Keywords: cell, zevalin, improves, pfs, nhl, patients, usa-based

Cell's Zevalin improves PFS in NHL patients

Article | 27 October 2008

Print This

USA-based Cell Therapeutics says that data from the FIT trial showed that Zevalin ([90Y]-ibritumomab tiuxetan) in consolidation therapy after ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in